Dublin, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Breast Cancer: HR+/HER2-" report to their offering.

Ibrance's continued uptake and the approvals of several pipeline therapies will drive the growth of the HR+/HER2- breast cancer market.

This report addresses the following questions:

- Which branded therapies will have the largest impact on the HR+/HER2- breast cancer market?
- What is the overall market potential for first-in-class product Ibrance?
- How will competing CDK4/6 inhibitors ribociclib and abemaciclib fare following the earlier launch of Ibrance?
- How will PI3K inhibitors alpelisib, buparlisib, and taselisib be positioned in the market?
- When will generic and biosimilar therapies enter the market and what impact will they have on revenues?

Key Topics Covered:

FORECAST: HR+/HER2 BREAST CANCER

- Abemaciclib
- Afinitor (everolimus)
- Alpelisib
- Avastin (bevacizumab)
- Buparlisib
- Entinostat
- Faslodex (fulvestrant)
- Halaven (eribulin mesylate)
- Ibrance (palbociclib)
- Ixempra (ixabepilone)
- Lynparza (olaparib)
- Niraparib
- Ribociclib
- Talazoparib
- Taselisib
- Veliparib
- Primary Research Methodology

TREATMENT: HR+/HER2 BREAST CANCER

- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in HR+/HER
- Breast Cancer

EPIDEMIOLOGY: HER+/HER2 BREAST CANCER

- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: HR+/HER2 BREAST CANCER

- Product profile: Afinitor
- Product profile: Avastin
- Product profile: Faslodex
- Product profile: Halaven
- Product profile: Ibrance
- Product profile: Ixempra

PIPELINE: HR+/HER2 BREAST CANCER

- Product profile (late stage): Lynparza
- Product profile (late stage): abemaciclib
- Product profile (late stage): alpelisib
- Product profile (late stage): buparlisib
- Product profile (late stage): entinostat
- Product profile (late stage): niraparib
- Product profile (late stage): ribociclib
- Product profile (late stage): talazoparib
- Product profile (late stage): taselisib
- Product profile (late stage): veliparib

For more information visit http://www.researchandmarkets.com/research/2slmd4/breast_cancer

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.